WAVE LIFE SCIENCES LTD. Share-based Payment Arrangement, Noncash Expense
WAVE LIFE SCIENCES LTD. (WVE) reported Share-based Payment Arrangement, Noncash Expense of $2.14 million for the 6-month period ending 2016-06-30, per its 10-Q filed 2016-08-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2016-08-15
- WAVE LIFE SCIENCES LTD. share-based payment arrangement, noncash expense for the quarter ending 2016-06-30 was $1.27M, a 96.59% increase year-over-year.
- WAVE LIFE SCIENCES LTD. share-based payment arrangement, noncash expense for the quarter ending 2016-03-31 was $866.00K, a 53.09% decline year-over-year.
- WAVE LIFE SCIENCES LTD. share-based payment arrangement, noncash expense for the quarter ending 2015-12-31 was $814.00K.
- WAVE LIFE SCIENCES LTD. share-based payment arrangement, noncash expense for the quarter ending 2015-09-30 was $718.00K.
- WAVE LIFE SCIENCES LTD. share-based payment arrangement, noncash expense for fiscal 2015 was $4.02M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2016-06-30 | $1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $2.14M 10-Q · filed 2016-08-15 | $2.95M derived: sum of 3 quarters · filed 2016-08-15 | $3.67M derived: sum of 4 quarters · filed 2016-08-15 |
| 2016-03-31 | $866.00K 10-Q · filed 2016-05-16 | $1.68M derived: sum of 2 quarters · filed 2016-05-16 | $2.40M derived: sum of 3 quarters · filed 2016-05-16 | $3.04M derived: sum of 4 quarters · filed 2016-08-15 |
| 2015-12-31 | $814.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $1.53M derived: sum of 2 quarters · filed 2016-03-30 | $2.18M derived: sum of 3 quarters · filed 2016-08-15 | $4.02M 10-K · filed 2016-03-30 |
| 2015-09-30 | $718.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-12-17 | $1.36M derived: sum of 2 quarters · filed 2016-08-15 | $3.21M 10-Q · filed 2015-12-17 | |
| 2015-06-30 | $646.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $2.49M 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | $1.85M 10-Q · filed 2016-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |